Effect of combined interferon-α induction therapy and ribavirin on chronic hepatitis C virus infection: A randomized multicentre study

Scandinavian Journal of Gastroenterology

Volumn 37, Issue 2, 2002, Pages 226-232

  Bjøro, Kristian ^a   Bell, H ^a   Hellum, K B ^a   Skaug, K ^a   Raknerud, N ^a   Sandvei, P ^a   Doskeland B ^a   Maeland A ^a   Lund Tonnesen S ^a   Myrvang, B ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Hepatitis C; Interferon; Ribavirin

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENDER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS; STEATOSIS; THROMBOCYTOPENIA; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LOGISTIC MODELS; MALE; RIBAVIRIN;

EID: 17944392178     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655202753416920     Document Type: Article

References (21)

1. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group
2. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks
3. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy
4. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group
5. Transfusion-associated chronic hepatitis C: Alpha-n1 interferon for 6 vs. 12 months
6. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
7. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
8. Comparison of high initial and fixed-dose regimens of interferon-alpha2a in chronic hepatitis C: A randomized controlled trial
9. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
10. Interferon alfacon-1 induction therapy: A multicenter trial in subjects with chronic hepatitis C virus infection
11. Failure of interferon induction dosing to alter sustained response rates in patients with chronic hepatitis C
12. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group
13. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globuline
14. Improvement of HCV genom detection with 'short' PCR products
15. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
16. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
17. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT
18. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3
19. Utility of early testing for HCV viremia as predictive factor of sustained response during interferon or interferon plus ribavirin treatment
20. Factors predictive of a beneficial response to therapy of hepatitis C
21. Factors predictive of response to interferon-α therapy in hepatitis C virus infection